Peringkat dalam Saham
#41692
Vaxxinity, Inc., a biotechnology company founded in 2014 and headquartered in... Vaxxinity, Inc., a biotechnology company founded in 2014 and headquartered in Dallas, Texas, is dedicated to advancing novel therapeutic candidates for human application in the United States. Its primary areas of focus are neurological disorders and infectious diseases, particularly those caused by coronaviruses. The company's pipeline features several key programs: UB-311 is a Phase 2 clinical trial candidate targeting toxic aggregated amyloid-beta proteins in the brain, aiming to treat Alzheimer's disease. UB-312, currently in Phase 1 clinical trials, is an investigational therapy designed to address Parkinson's disease and other synucleinopathies, including Lewy body dementia and multiple system atrophy, by targeting detrimental aggregated alpha-synuclein. An anti-tau product candidate is also under development for various neurodegenerative conditions, such as Alzheimer's disease. UB-313 is being developed to alleviate migraines by modulating calcitonin gene-related peptide. An anti-PCSK9 candidate aims to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events by targeting proprotein convertase subtilisin/kexin type 9 serine protease. In the infectious disease segment, UB-612 is a Phase 3 clinical-stage candidate engineered to neutralize the SARS-CoV-2 virus.
Harga Saham
$0.0001
Terakhir disinkronkan: 2026-08-11
Kapitalisasi Pasar
$12.68K
Perubahan (1 tahun)
-99.76%
Perdagangan Vaxxinity, Inc. (VAXX)
Pendapatan untuk Vaxxinity, Inc. (VAXX)
Pendapatan pada Aug 2026 TTM: 0
Menurut laporan keuangan terbaru dari Vaxxinity, Inc., pendapatan saat ini (TTM) adalah 0. Pada tahun 2026, perusahaan menghasilkan pendapatan sebesar 0 sama dengan pendapatan pada tahun 2026 yang sebesar 0. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Vaxxinity, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun |
Pendapatan |
Mengubah |
|
Tidak cukup data untuk tanggal yang disediakan. |
Pendapatan untuk perusahaan serupa atau pesaing
| Perusahaan |
Pendapatan |
Perbedaan Pendapatan |
Negara |
|
|
$12.62B |
-
|
US
|
|
|
$6.02B |
-
|
NL
|
|
|
- |
-
|
CH
|
|
|
$10.11B |
-
|
BE
|
|
|
- |
-
|
KR
|
